US-India Trade Progress
US and India Advance Interim Trade Deal, Section 301 Probes Key to Finalization
Anonymous
Key Points
1
A Section 301 probe covering 60 countries is the last major step before finalizing the India–US trade deal; one senior official indicated that this probe is expected to conclude soon, potentially unlocking tariff decisions.
2
Jaishankar highlighted 'critical minerals and artificial intelligence' as priority areas within the India–US Comprehensive Global Strategic Partnership, alongside trade, tariffs, energy, and security.
3
U.S. trade-sensitivities include potential tariffs up to 12.5% on goods from countries suspected of forced-labor in their supply chains, with India among those nations under consideration.
4
There is a possibility that the deal could wrap up within three to four months but progress is contingent on ongoing Section 301 investigations—a point highlighted by a senior US official.
5
If the deal proceeds, the U.S. has indicated a two-year tariff exemption for generic medicines, with Indian pharma exports to the U.S. comprising a substantial share (about 38% in 2025).
A landmark trade deal between the United States and India could be signed within three to four months, according to a senior U.S. official Yahoo Finance. The agreement aims to expand market access and lower trade barriers, bringing the world's two largest democracies closer economically.
Senior officials from both countries met in Manila, where talks were described as nearly complete Dubai Eye. The deal is part of a broader India–U.S. Comprehensive Global Strategic Partnership covering trade, energy, and security.
Section 301 Probe Stands Between Talks and a Deal
One key hurdle remains: a U.S. Section 301 investigation. This probe reviews alleged unfair trade practices across 60 countries, including India Newsmax. A senior U.S. official said the investigation is expected to wrap up soon. Once it does, tariff decisions can be made and the deal can move forward.
Section 301 gives the U.S. government power to impose tariffs on countries it believes engage in unfair trade. The probe's conclusion is now seen as the last major step before both sides can sign ARN News Centre.
Pharma Tariffs and Forced-Labor Duties Add Pressure
Tariffs on generic medicines are a major concern for India. Indian pharma exports made up about 38% of U.S. generic drug imports in 2025 Whalesbook. The U.S. has floated a two-year tariff exemption for generic medicines, which would give Indian drug makers temporary relief.
The U.S. is also considering duties of up to 12.5% on goods from countries with forced labor in their supply chains. India is among the nations under review Yahoo Finance. These potential tariffs could shape the final terms of the agreement.
Critical Minerals and AI Emerge as Top Priorities
Indian Foreign Minister S. Jaishankar pointed to critical minerals and artificial intelligence as priority areas in the partnership Dubai Eye. Both sectors are seen as vital for long-term economic and security cooperation between the two nations.
The Manila talks also covered defense commitments tied to Trump–Modi agreements and broader Indo-Pacific issues. Officials on both sides stressed the urgency of finalizing the deal quickly ARN News Centre.
Three-to-Four Month Window Hinges on U.S. Investigations
The three-to-four month timeline is not guaranteed. Progress depends on how fast U.S. internal investigations conclude Newsmax. Any delays in the Section 301 probe could push back the signing date.
Still, investors and policymakers are watching closely. A finalized deal would mark a major step in aligning two of the world's biggest economies — and could reshape supply chains across Asia Whalesbook.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
81
Reach
93
A
AnonymousAuthor